3-炔基-6-芳基-异噻唑[4,3-b]吡啶作为脂质激酶PIKfyve和PIP4K2C双抑制剂的构效关系研究

IF 4.8 3区 医学 Q2 CHEMISTRY, MEDICINAL
Pharmaceuticals Pub Date : 2025-09-06 DOI:10.3390/ph18091341
Demian Kalebic, Ling-Jie Gao, Belén Martinez-Gualda, Marwah Karim, Sirle Saul, Do Hoang Nhu Tran, Jef Rozenski, Leentje Persoons, Dominique Schols, Wim Dehaen, Shirit Einav, Steven De Jonghe
{"title":"3-炔基-6-芳基-异噻唑[4,3-b]吡啶作为脂质激酶PIKfyve和PIP4K2C双抑制剂的构效关系研究","authors":"Demian Kalebic, Ling-Jie Gao, Belén Martinez-Gualda, Marwah Karim, Sirle Saul, Do Hoang Nhu Tran, Jef Rozenski, Leentje Persoons, Dominique Schols, Wim Dehaen, Shirit Einav, Steven De Jonghe","doi":"10.3390/ph18091341","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: RMC-113, a 3-alkynyl-6-aryl-disubstituted isothiazolo[4,3-<i>b</i>]pyridine, is a dual inhibitor of the lipid kinases PIKfyve and PIP4K2C with broad-spectrum antiviral activity. The aim was to study the structure-activity relationship (SAR) of isothiazolo[4,3-<i>b</i>]pyridines as dual PIKfyve/PIP4K2C inhibitors. <b>Methods</b>: A series of isothiazolo[4,3-<i>b</i>]pyridines was synthesized by introducing structural variety at positions 3 and 6 of the central scaffold. The primary assay to guide the synthetic chemistry was a biochemical PIKfyve assay, with a number of analogues also tested for PIP4K2C binding affinity. Finally, isothiazolo[4,3-<i>b</i>]pyridines were also evaluated for antiviral and antitumoral activity in cell-based assays. <b>Results</b>: PIKfyve inhibition tolerated a wide variety of substituents on the aryl ring at position 6 of the isothiazolo[4,3-<i>b</i>]pyridine scaffold, with the 4-carboxamide analogue emerging as the most potent (IC<sub>50</sub> = 1 nM). The SAR at position 3 was more restricted, although the introduction of electron-donating groups (such as a methyl and methoxy) on the pyridinyl ring yielded potent PIKfyve inhibitors, with IC<sub>50</sub> values in the low nM range. The acetylenic moiety was essential for PIKfyve inhibition, and only the saturated ethyl linker displayed potent PIKfyve inhibition, albeit less active than the acetylene counterpart. The compounds were 2- to 5-fold less potent on PIP4K2C relative to PIKfyve. These dual PIKfyve/PIP4K2C inhibitors displayed antiviral activity against both the venezuelan equine encephalitis virus (VEEV) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A screening against a panel of cancer cell lines revealed antitumoral activity, although some of the potent PIKfyve/PIP5K2C inhibitors lacked antitumoral activity. <b>Conclusions</b>: Isothiazolo[4,3-<i>b</i>]pyridines are dual PIKfyve/PIP4K2C inhibitors displaying broad-spectrum antiviral, as well as antitumoral, activity.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 9","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472322/pdf/","citationCount":"0","resultStr":"{\"title\":\"Structure-Activity Relationship Study of 3-Alkynyl-6-aryl-isothiazolo[4,3-<i>b</i>]pyridines as Dual Inhibitors of the Lipid Kinases PIKfyve and PIP4K2C.\",\"authors\":\"Demian Kalebic, Ling-Jie Gao, Belén Martinez-Gualda, Marwah Karim, Sirle Saul, Do Hoang Nhu Tran, Jef Rozenski, Leentje Persoons, Dominique Schols, Wim Dehaen, Shirit Einav, Steven De Jonghe\",\"doi\":\"10.3390/ph18091341\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background/Objectives</b>: RMC-113, a 3-alkynyl-6-aryl-disubstituted isothiazolo[4,3-<i>b</i>]pyridine, is a dual inhibitor of the lipid kinases PIKfyve and PIP4K2C with broad-spectrum antiviral activity. The aim was to study the structure-activity relationship (SAR) of isothiazolo[4,3-<i>b</i>]pyridines as dual PIKfyve/PIP4K2C inhibitors. <b>Methods</b>: A series of isothiazolo[4,3-<i>b</i>]pyridines was synthesized by introducing structural variety at positions 3 and 6 of the central scaffold. The primary assay to guide the synthetic chemistry was a biochemical PIKfyve assay, with a number of analogues also tested for PIP4K2C binding affinity. Finally, isothiazolo[4,3-<i>b</i>]pyridines were also evaluated for antiviral and antitumoral activity in cell-based assays. <b>Results</b>: PIKfyve inhibition tolerated a wide variety of substituents on the aryl ring at position 6 of the isothiazolo[4,3-<i>b</i>]pyridine scaffold, with the 4-carboxamide analogue emerging as the most potent (IC<sub>50</sub> = 1 nM). The SAR at position 3 was more restricted, although the introduction of electron-donating groups (such as a methyl and methoxy) on the pyridinyl ring yielded potent PIKfyve inhibitors, with IC<sub>50</sub> values in the low nM range. The acetylenic moiety was essential for PIKfyve inhibition, and only the saturated ethyl linker displayed potent PIKfyve inhibition, albeit less active than the acetylene counterpart. The compounds were 2- to 5-fold less potent on PIP4K2C relative to PIKfyve. These dual PIKfyve/PIP4K2C inhibitors displayed antiviral activity against both the venezuelan equine encephalitis virus (VEEV) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A screening against a panel of cancer cell lines revealed antitumoral activity, although some of the potent PIKfyve/PIP5K2C inhibitors lacked antitumoral activity. <b>Conclusions</b>: Isothiazolo[4,3-<i>b</i>]pyridines are dual PIKfyve/PIP4K2C inhibitors displaying broad-spectrum antiviral, as well as antitumoral, activity.</p>\",\"PeriodicalId\":20198,\"journal\":{\"name\":\"Pharmaceuticals\",\"volume\":\"18 9\",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-09-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472322/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/ph18091341\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18091341","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:rmmc -113是一种3-炔基-6-芳基-二取代异噻唑[4,3-b]吡啶,是一种具有广谱抗病毒活性的脂质激酶PIKfyve和PIP4K2C的双重抑制剂。目的是研究异噻唑[4,3-b]吡啶作为PIKfyve/PIP4K2C双抑制剂的构效关系(SAR)。方法:通过在中心支架的3、6位引入结构变化,合成一系列异噻唑[4,3-b]吡啶。指导合成化学的主要实验是生化PIKfyve实验,还有一些类似物也测试了PIP4K2C的结合亲和力。最后,异噻唑[4,3-b]吡啶也在基于细胞的实验中评估了抗病毒和抗肿瘤活性。结果:PIKfyve对异噻唑[4,3-b]吡啶支架上芳基环6位上的多种取代基具有抑制作用,其中4-羧酰胺类似物的抑制作用最强(IC50 = 1 nM)。虽然在吡啶环上引入给电子基团(如甲基和甲氧基)产生了有效的PIKfyve抑制剂,但位置3的SAR更受限制,IC50值在低nM范围内。乙炔部分对抑制PIKfyve至关重要,只有饱和乙基连接物显示出有效的PIKfyve抑制作用,尽管活性低于乙炔对应物。这些化合物对PIP4K2C的作用比PIKfyve低2- 5倍。这些PIKfyve/PIP4K2C双抑制剂对委内瑞拉马脑炎病毒(VEEV)和严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)均显示抗病毒活性。尽管一些有效的PIKfyve/PIP5K2C抑制剂缺乏抗肿瘤活性,但对一组癌细胞系的筛选显示出抗肿瘤活性。结论:异噻唑类[4,3-b]吡啶类是PIKfyve/PIP4K2C双抑制剂,具有广谱抗病毒和抗肿瘤活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Structure-Activity Relationship Study of 3-Alkynyl-6-aryl-isothiazolo[4,3-b]pyridines as Dual Inhibitors of the Lipid Kinases PIKfyve and PIP4K2C.

Background/Objectives: RMC-113, a 3-alkynyl-6-aryl-disubstituted isothiazolo[4,3-b]pyridine, is a dual inhibitor of the lipid kinases PIKfyve and PIP4K2C with broad-spectrum antiviral activity. The aim was to study the structure-activity relationship (SAR) of isothiazolo[4,3-b]pyridines as dual PIKfyve/PIP4K2C inhibitors. Methods: A series of isothiazolo[4,3-b]pyridines was synthesized by introducing structural variety at positions 3 and 6 of the central scaffold. The primary assay to guide the synthetic chemistry was a biochemical PIKfyve assay, with a number of analogues also tested for PIP4K2C binding affinity. Finally, isothiazolo[4,3-b]pyridines were also evaluated for antiviral and antitumoral activity in cell-based assays. Results: PIKfyve inhibition tolerated a wide variety of substituents on the aryl ring at position 6 of the isothiazolo[4,3-b]pyridine scaffold, with the 4-carboxamide analogue emerging as the most potent (IC50 = 1 nM). The SAR at position 3 was more restricted, although the introduction of electron-donating groups (such as a methyl and methoxy) on the pyridinyl ring yielded potent PIKfyve inhibitors, with IC50 values in the low nM range. The acetylenic moiety was essential for PIKfyve inhibition, and only the saturated ethyl linker displayed potent PIKfyve inhibition, albeit less active than the acetylene counterpart. The compounds were 2- to 5-fold less potent on PIP4K2C relative to PIKfyve. These dual PIKfyve/PIP4K2C inhibitors displayed antiviral activity against both the venezuelan equine encephalitis virus (VEEV) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A screening against a panel of cancer cell lines revealed antitumoral activity, although some of the potent PIKfyve/PIP5K2C inhibitors lacked antitumoral activity. Conclusions: Isothiazolo[4,3-b]pyridines are dual PIKfyve/PIP4K2C inhibitors displaying broad-spectrum antiviral, as well as antitumoral, activity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmaceuticals
Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.10
自引率
4.30%
发文量
1332
审稿时长
6 weeks
期刊介绍: Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信